#United States #Los Angeles #Securities Fraud #Glancy Prongay #Tenax Therapeutics

What's Next for Tenax Therapeutics Shareholders?

In a dramatic financial downturn, Tenax Therapeutics, Inc. has seen its stock plummet by an astounding 89.77%. This drop represents a significant concern for shareholders and presents an opportunity to leverage legal recourse through class action lawsuits. Glancy Prongay Wolke & Rotter LLP, a prominent law firm focused on securities fraud, has taken steps to assist affected investors with this situation.

Overview of the Situation

The class action lawsuit pertains to investors who acquired Tenax Therapeutics securities between November 13, 2023, and August 7, 2026. Glancy Prongay announced the lawsuit, which was filed in the U.S. District Court for the Middle District of North Carolina on October 26, 2026. Investors who suffered losses due to the stock decline are encouraged to consider their options, especially with the looming deadline of December 28, 2026, to file for lead plaintiff status.

What Led to the Stock Decline?

The steep decline can be attributed to alarming results from Tenax's Phase 3 LEVEL clinical trial, announced on August 10, 2026. The key findings revealed that TNX-103, a potential treatment evaluated in the trial, failed to meet expected clinical endpoints. The specific statements indicated the treatment did not significantly improve walking distance compared to a placebo, nor did it enhance the quality of life for patients as assessed by the Kansas City Cardiomyopathy Questionnaire total symptom score.

In the wake of this news, Tenax’s stock price fell sharply by $12.06 per share, culminating in a close of $1.38 on the trading floor – a clear indicator of investor disappointment and erasure of market confidence.

Allegations in the Class Action

The core of the allegations against Tenax Therapeutics highlights misleading communications. The lawsuit claims that between November 13, 2023, and August 7, 2026, the company's executives made materially false and misleading statements concerning the efficacy and prospects of TNX-103. Specifically, the complaint points out that:

1. Underestimated Drug Efficacy: The executives allegedly clouded the actual effectiveness of TNX-103 as better than it was, which misled investors about its clinical potential.
2. Overstated Commercial Viability: Assertions regarding the drug's anticipated success and broader market acceptance were allegedly significantly inflated.
3. Lack of Transparency: Vital information about the true status of TNX-103 and its prospects was omitted, thereby misguiding investors regarding the risks involved.

The ramifications of this conduct necessitate legal action for restitution from individuals who made investments under these misleading circumstances.

Next Steps for Investors

For those impacted, the timeline is critical. Investors can submit their loss details to Glancy Prongay Wolke & Rotter LLP, with the lead plaintiff deadline set for December 28, 2026. Anyone wishing to represent the class must file a motion with the court by this date.

Charles H. Linehan, a partner at Glancy, states that this deadline marks an essential juncture for potential class members. It’s crucial for shareholders to keep their rights intact and assume an active role if they wish to participate in the legal proceedings.

Frequently Asked Questions

• - Who is eligible? Investors who acquired Tenax's securities during the stipulated class period and experienced losses might qualify for participation in the lawsuit.
• - What constitutes a lead plaintiff? This role is typically awarded to an investor or group of investors demonstrating the largest financial stake in the outcome of the lawsuit.
• - Do you need to be a lead plaintiff to recover losses? No. Recovery does not depend on lead plaintiff status, allowing investors the option to remain passive if preferred.
• - How can Glancy assist? Investors can enlist the law firm’s services without upfront fees; expenses only arise contingent to a favorable recovery.

Conclusion

As the situation develops, Tenax Therapeutics shareholders should stay informed and consider their options seriously. Engaging with experienced legal representation, such as Glancy Prongay Wolke & Rotter LLP, could potentially provide a path to regain lost investments through upcoming legal actions. For further assistance or to begin the process, investors can visit the case page or contact Glancy directly via phone or email.

Investors, remember, taking timely action is crucial in securing rights and navigating these turbulent waters.